人口老龄化背景下老年肝癌的现状分析
Analysis of the Current Situation of Liver Cancer in the Elderly under the Background of Population Aging
DOI: 10.12677/ar.2025.125056, PDF,   
作者: 李玮琦：上海理工大学健康科学与工程学院，上海
关键词: 人口老龄化；肝细胞癌；流行病学；危险因素；预防；Population Aging； Hepatocellular Carcinoma； Epidemiology； Risk Factors； Prevention
摘要: 随着全球人口老龄化现象日益凸显，老年人群体中肝癌的发病率和致命性呈现出明显的上升趋势。针对这一问题，本文进行了深入的分析，探讨了老年人肝癌的流行病学特征、危险因素、诊疗策略以及预防措施。通过对全球范围以及各地区的相关数据进行综合研究，揭示了老龄化对肝癌疾病负担的影响，为未来制定针对性的防控策略提供了重要参考依据。旨在有效减少老年人群体肝癌发病率的增长，保障老年人群体的健康福祉。
Abstract: With the increasingly prominent global phenomenon of population aging, the incidence and fatality of liver cancer among the elderly are showing a significant upward trend. In response to this issue, this article conducts an in-depth analysis, discussing the epidemiological characteristics, risk factors, diagnosis and treatment strategies, and preventive measures of liver cancer in the elderly. Through comprehensive research on relevant data at a global and regional level, it reveals the impact of aging on the burden of liver cancer, providing an important reference for the development of targeted prevention and control strategies in the future. Aiming to effectively reduce the increasing incidence rate of liver cancer among the elderly and safeguard their health and well-being.
文章引用：李玮琦. 人口老龄化背景下老年肝癌的现状分析[J]. 老龄化研究, 2025, 12(5): 407-412. https://doi.org/10.12677/ar.2025.125056

参考文献

[1] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263. [Google Scholar] [CrossRef] [PubMed]
[2] Rumgay, H., Arnold, M., Ferlay, J., Lesi, O., Cabasag, C.J., Vignat, J., et al. (2022) Global Burden of Primary Liver Cancer in 2020 and Predictions to 2040. Journal of Hepatology, 77, 1598-1606. [Google Scholar] [CrossRef] [PubMed]
[3] 缪伟刚, 周金意, 韩仁强. 全球肝癌流行数据解析[J]. 中华流行病学杂志, 2024, 45(6): 865-869.
[4] Institute for Health Metrics and Evaluation (IHME) (2023) GBD Results.
https://vizhub.healthdata.org/gbd-results/
[5] 赫捷, 陈万青, 沈洪兵, 等. 中国人群肝癌筛查指南(2022, 北京) [J]. 临床肝胆病杂志, 2022, 38(8): 1739-1758.
[6] Zheng, R., Qu, C., Zhang, S., Zeng, H., Sun, K., Gu, X., et al. (2018) Liver Cancer Incidence and Mortality in China: Temporal Trends and Projections to 2030. Chinese Journal of Cancer Research, 30, 571-579. [Google Scholar] [CrossRef] [PubMed]
[7] Lin, L., Yan, L., Liu, Y., Qu, C., Ni, J. and Li, H. (2020) The Burden and Trends of Primary Liver Cancer Caused by Specific Etiologies from 1990 to 2017 at the Global, Regional, National, Age, and Sex Level Results from the Global Burden of Disease Study 2017. Liver Cancer, 9, 563-582. [Google Scholar] [CrossRef] [PubMed]
[8] Liu, Z., Jiang, Y., Yuan, H., Fang, Q., Cai, N., Suo, C., et al. (2019) The Trends in Incidence of Primary Liver Cancer Caused by Specific Etiologies: Results from the Global Burden of Disease Study 2016 and Implications for Liver Cancer Prevention. Journal of Hepatology, 70, 674-683. [Google Scholar] [CrossRef] [PubMed]
[9] Forbes, A. and Williams, R. (1990) Changing Epidemiology and Clinical Aspects of Hepatitis A. British Medical Bulletin, 46, 303-318. [Google Scholar] [CrossRef] [PubMed]
[10] Trépo, C., Chan, H.L.Y. and Lok, A. (2014) Hepatitis B Virus Infection. The Lancet, 384, 2053-2063. [Google Scholar] [CrossRef] [PubMed]
[11] Sugauchi, F., Mizokami, M., Orito, E., Ohno, T., Kato, H., Maki, M., et al. (2000) Hepatitis B Virus Infection among Residents of a Nursing Home for the Elderly: Seroepidemiological Study and Molecular Evolutionary Analysis. Journal of Medical Virology, 62, 456-462. [Google Scholar] [CrossRef] 
[12] Pardee, M. (2019) Diagnosis and Management of Hepatitis B and C. Nursing Clinics of North America, 54, 277-284. [Google Scholar] [CrossRef] [PubMed]
[13] de Martel, C., Maucort‐Boulch, D., Plummer, M. and Franceschi, S. (2015) World‐Wide Relative Contribution of Hepatitis B and C Viruses in Hepatocellular Carcinoma. Hepatology, 62, 1190-1200. [Google Scholar] [CrossRef] [PubMed]
[14] Junaidi, O. and Di Bisceglie, A.M. (2007) Aging Liver and Hepatitis. Clinics in Geriatric Medicine, 23, 889-903. [Google Scholar] [CrossRef] [PubMed]
[15] Estes, C., Anstee, Q.M., Arias-Loste, M.T., Bantel, H., Bellentani, S., Caballeria, J., et al. (2018) Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the Period 2016-2030. Journal of Hepatology, 69, 896-904. [Google Scholar] [CrossRef] [PubMed]
[16] Li, J., Zou, B., Yeo, Y.H., Feng, Y., Xie, X., Lee, D.H., et al. (2019) Prevalence, Incidence, and Outcome of Non-Alcoholic Fatty Liver Disease in Asia, 1999-2019: A Systematic Review and Meta-Analysis. The Lancet Gastroenterology & Hepatology, 4, 389-398. [Google Scholar] [CrossRef] [PubMed]
[17] Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L. and Wymer, M. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Disease—Meta‐Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology, 64, 73-84. [Google Scholar] [CrossRef] [PubMed]
[18] Angulo, P., Keach, J.C., Batts, K.P. and Lindor, K.D. (1999) Independent Predictors of Liver Fibrosis in Patients with Nonalcoholic Steatohepatitis. Hepatology, 30, 1356-1362. [Google Scholar] [CrossRef] [PubMed]
[19] Huang, D.Q., El-Serag, H.B. and Loomba, R. (2020) Global Epidemiology of NAFLD-Related HCC: Trends, Predictions, Risk Factors and Prevention. Nature Reviews Gastroenterology & Hepatology, 18, 223-238. [Google Scholar] [CrossRef] [PubMed]
[20] 涂文升. 广西人群血清中游离黄曲霉毒素B1含量、肝组织中黄曲霉毒素B-DNA加合物的表达、AFB1暴露水平与肝癌发生的关系[J]. 世界最新医学信息文摘, 2015(16): 116-117.
[21] Nugraha, A., Khotimah, K. and Rietjens, I.M.C.M. (2018) Risk Assessment of Aflatoxin B1 Exposure from Maize and Peanut Consumption in Indonesia Using the Margin of Exposure and Liver Cancer Risk Estimation Approaches. Food and Chemical Toxicology, 113, 134-144. [Google Scholar] [CrossRef] [PubMed]
[22] 王君, 刘秀梅, 张志强. 中国人群膳食黄曲霉毒素致肝癌的暴露评估[J]. 中华预防医学杂志, 2009, 43(6): 478-481.
[23] Zeng, R.W., Ong, C.E.Y., Ong, E.Y.H., Chung, C.H., Lim, W.H., Xiao, J., et al. (2024) Global Prevalence, Clinical Characteristics, Surveillance, Treatment Allocation, and Outcomes of Alcohol-Associated Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 22, 2394-2402.E15. [Google Scholar] [CrossRef] [PubMed]
[24] Mirici-Cappa, F., Gramenzi, A., Santi, V., Zambruni, A., Di Micoli, A., Frigerio, M., et al. (2010) Treatments for Hepatocellular Carcinoma in Elderly Patients Are as Effective as in Younger Patients: A 20-Year Multicentre Experience. Gut, 59, 387-396. [Google Scholar] [CrossRef] [PubMed]
[25] Cohen, M.J., Bloom, A.I., Barak, O., Klimov, A., Nesher, T., Shouval, D., et al. (2013) Trans-Arterial Chemo-Embolization Is Safe and Effective for Very Elderly Patients with Hepatocellular Carcinoma. World Journal of Gastroenterology, 19, 2521-2528. [Google Scholar] [CrossRef] [PubMed]
[26] Wong, H., Tang, Y.F., Yao, T., Chiu, J., Leung, R., Chan, P., et al. (2011) The Outcomes and Safety of Single-Agent Sorafenib in the Treatment of Elderly Patients with Advanced Hepatocellular Carcinoma (HCC). The Oncologist, 16, 1721-1728. [Google Scholar] [CrossRef] [PubMed]
[27] Edeline, J., Crouzet, L., Le Sourd, S., Larible, C., Brunot, A., Le Roy, F., et al. (2014) Sorafenib Use in Elderly Patients with Hepatocellular Carcinoma: Caution about Use of Platelet Aggregation Inhibitors. Cancer Chemotherapy and Pharmacology, 75, 215-219. [Google Scholar] [CrossRef] [PubMed]
[28] Tada, T., Kumada, T., Hiraoka, A., Michitaka, K., Atsukawa, M., Hirooka, M., et al. (2019) Safety and Efficacy of Lenvatinib in Elderly Patients with Unresectable Hepatocellular Carcinoma: A Multicenter Analysis with Propensity Score Matching. Hepatology Research, 50, 75-83. [Google Scholar] [CrossRef] [PubMed]

为你推荐